We found that LIN9, MYBL1, and MYBL2 in BRCA; RBL1, MYBL2, and RBL2 in KIRC; RBL1, MYBL2 and RBL2 in LUAD; LIN9, LIN54, MYBL2, and TFDP1 in STAD; LIN9 and RBBP4 in HNSC; LIN9, RBBP4, and LIN54 in LUSC; LIN9 and MYBL1, RBL1 and LIN52 in BLCA were significantly differentially expressed (p < 0.05, Figure 1C). Here, MYBL2 is linked to bladder transitional cell carcinoma.